Moderna (MRNA) Payables (2017 - 2026)
Moderna (MRNA) posted quarterly Payables of $167.0 million for Q2 2026, down 4.57% year-over-year from $175.0 million in Q2 2025, and up 3.73% on a QoQ basis from $161.0 million in Q1 2026.
Moderna (MRNA) Payables (2017 - 2026) Analysis & Trends
Moderna has reported Payables for 10 years, with the latest figure at $167.0 million in Q2 2026.
- Payables for Q2 2026 came in at $167.0 million, down 4.57% year-over-year; the trailing twelve-month figure through Jun 2026 was $167.0 million (down 4.57% YoY), and the FY2025 annual result was $317.0 million, down 21.73% from the prior year.
- Payables climbed to $167.0 million in Q2 2026, from $161.0 million in the prior quarter.
- Over five years, Payables peaked at $520.0 million in Q4 2023 and troughed at $161.0 million in Q1 2026.
- A 5-year average of $303.5 million and a median of $294.5 million in 2023 frame the typical range for Payables.
- The widest annual swing landed in 2022, when Payables jumped 2387.5%; it then slumped 52.96% in 2024.
- A 5-year view of Payables shows it stood at $487.0 million in 2022, then increased by 6.78% to $520.0 million in 2023, then decreased by 22.12% to $405.0 million in 2024, then declined by 21.73% to $317.0 million in 2025, then plunged by 47.32% to $167.0 million in 2026.
- Per Business Quant data, the three most recent Payables figures were $167.0 million in Q2 2026, $161.0 million in Q1 2026, and $317.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Moderna | 25.26 Bn | 20.13 Bn | 52.00 Mn | 167.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 167.00 Mn |
| Mar 31, 2026 | 161.00 Mn |
| Dec 31, 2025 | 317.00 Mn |
| Sep 30, 2025 | 267.00 Mn |
| Jun 30, 2025 | 175.00 Mn |
| Mar 31, 2025 | 226.00 Mn |
| Dec 31, 2024 | 405.00 Mn |
| Sep 30, 2024 | 373.00 Mn |
| Jun 30, 2024 | 279.00 Mn |
| Mar 31, 2024 | 183.00 Mn |
| Dec 31, 2023 | 520.00 Mn |
| Sep 30, 2023 | 494.00 Mn |
| Jun 30, 2023 | 310.00 Mn |
| Mar 31, 2023 | 389.00 Mn |
| Dec 31, 2022 | 487.00 Mn |
| Sep 30, 2022 | 330.00 Mn |
| Jun 30, 2022 | 181.00 Mn |
| Mar 31, 2022 | 199.00 Mn |
| Dec 31, 2021 | 302.00 Mn |
| Sep 30, 2021 | 87.00 Mn |